Amgen stock gains on Novo Nordisk's weightloss drug blunder

Amgen stock gains on drug results of Novo Nordisk.
Novo Nordisk's CagriSema drug reduced testings subjects' weight less than expected.
Amgen itself has struggled with developing its MariTide weightloss drug.
AMGN stock has been in a downtrend since at least July.

Clay Webster FXStreet

Amgen stock gained more than 2% in Friday’s morning session after foreign weightloss drug competitor Novo Nordisk (NVO) plunged following the results of new drug testing. As one of the leaders in weightloss pharmaceuticals, the news led other pharma stocks to run higher.

The Dow Jones Industrial Average (DJIA) index surged 1.8%, its best outing in awhile and especially after its historic ten-session pullback ended on Thursday by a hair. The DJIA is leading the NASDAQ and S&P 500 moderately at the time of writing.

The US Personal Consumption Expenditures (PCE) report for November is also cheering stock investors after Wednesday and Thursday witnessed widespread negativity over the Fed’s hawkish outlook. US inflation in the PCE arrived lower than economists had projected, which may mean that the Fed’s worries over inflation are likely to clear up in subsequent reports.

Amgen stock news

Novo Nordisk, the Danish maker of the Wegovy and Ozempic weightloss drugs, released data on the third phase of testing for its new CagriSema drug. CagriSema is supposed to be its next-generation drug for weightloss.

However, the data showed that CagriSema caused users to lose 20% of their weight after 68 weeks. This was in line with existing weightloss medicines and well below the 25% guidance that Novo Nordisk had previously aimed for.

Eli Lilly’s (LLY) Zepbound already reduces weight among its users by 23%, according to similar testing. Since the weightloss drug industry is expected to grow to $150 billion annually by 2030, the competitive nature of the sector has pushed up the competitors to Novo Nordisk.

One of those competitors is Amgen, which has been testing the MariTide drug for the same purpose. The company released test results in late November that showed the drug caused weight loss of up to 20% in obese and overweight individuals over a 52-week period. However, the results also showed that it might be causing patients to lose bone mineral density.

Amgen stock forecast

Amgen’s Thursday low of $253.30 was its lowest price since October 31, 2023, but the pharma stock rode an afternoon wave of optimism to produce a near 1% gain by the close. Friday is confirmation that the mood has changed.

Shares have risen back above the $261 level that acted as support on a number of occasions in late 2023 and throughout 2024. If AMGN stock can retain this region above $261, then the worst may be over. Shares of the pharmaceutical corporation have been trending lower since achieving an all-time high in July of this year above $346.

Still, lows created on November 26 and December 19 below $261 lead us to believe that the bottom may not be in. A third break below $261 will have many traders expecting the stock to dump all the way to the May through July 2023 lows in the demand zone stretching from $211 to $218.

AMGN daily stock chart

Premium

You have reached your limit of 3 free articles for this month.

Start your subscription and get access to all our original articles.

Subscribe to Premium Sign In

Author

Clay Webster

FXStreet

Clay Webster grew up in the US outside Buffalo, New York and Lancaster, Pennsylvania. He began investing after college following the 2008 financial crisis.

GBP/USD loses momentum, flirts with 1.3200

GBP/USD is struggling to maintain its positive bias on Thursday, retreating toward the 1.3200 region in response to the pick in the buying interest around the Greenback. That said, Cable remains under scrutiny as cautious market sentiment keeps investors focused on the US-Iran conflict and political effervescence in the UK.

EUR/USD trims gains, challenges 1.1400

EUR/USD now gives away part of its earlier advance, receding toward the 1.1400 contention zone on Thursday. Meanwhile, the pair’s recovery comes amid extra losses in the US Dollar, at the time when while investors continue to monitor developments in the Middle East and sentiment surrounding global technology stocks.

Gold remains bid and close to $4,100

Gold accelerates its recovery and approaches the key $4,000 mark per troy ounce at the end of the week, adding to Thursday’s advance. However, expectations for a hawkish Fed remain steady and keep the yellow metal’s potential upside contained.

Crypto Today: Bitcoin at $60,000, Ethereum at $1,500, and XRP at $1 face a make-or-break test

Bitcoin (BTC), Ethereum (ETH), and Ripple (XRP) are trading in the red on Friday after three consecutive days of losses, testing their respective make-or-break support levels.

Week ahead – NFP report to challenge Dollar strength and the hawkish Fed

Dollar strength dominates markets, as the hawkish Fed overshadows geopolitics and lower oil prices. NFP week could drive September Fed hike expectations and boost market volatility. The euro lacks fresh bullish catalysts, all eyes on the preliminary inflation report and the ECB Forum.

Regime change: Inside Kevin Warsh's first move to make the Fed unreadable on purpose

The rate did not move. That was the least interesting thing about Kevin Warsh's first meeting in charge of the Fed. The FOMC held its benchmark at 3.50%-3.75% for the fourth straight meeting, exactly as priced, and then the new chair used his first press conference to dismantle the machinery the market has leaned on for a decade.